JP2003532675A - 癌細胞の増殖を阻害しそのアポトーシスを誘導する方法 - Google Patents
癌細胞の増殖を阻害しそのアポトーシスを誘導する方法Info
- Publication number
- JP2003532675A JP2003532675A JP2001581820A JP2001581820A JP2003532675A JP 2003532675 A JP2003532675 A JP 2003532675A JP 2001581820 A JP2001581820 A JP 2001581820A JP 2001581820 A JP2001581820 A JP 2001581820A JP 2003532675 A JP2003532675 A JP 2003532675A
- Authority
- JP
- Japan
- Prior art keywords
- leukotriene
- alkyl
- compound
- ethyl
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21934400P | 2000-05-09 | 2000-05-09 | |
US60/219,344 | 2000-05-09 | ||
PCT/US2001/040697 WO2001085166A1 (en) | 2000-05-09 | 2001-05-08 | Methods for inhibiting proliferation and inducing apoptosis in cancer cells |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2003532675A true JP2003532675A (ja) | 2003-11-05 |
Family
ID=22818912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001581820A Pending JP2003532675A (ja) | 2000-05-09 | 2001-05-08 | 癌細胞の増殖を阻害しそのアポトーシスを誘導する方法 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1326605A4 (ko) |
JP (1) | JP2003532675A (ko) |
KR (1) | KR20030019372A (ko) |
CN (1) | CN1237968C (ko) |
AU (1) | AU2001261832A1 (ko) |
BR (1) | BR0110473A (ko) |
CA (1) | CA2408622A1 (ko) |
MX (1) | MXPA02010974A (ko) |
NO (1) | NO20025343L (ko) |
NZ (1) | NZ522387A (ko) |
WO (1) | WO2001085166A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5858391B2 (ja) * | 2013-04-22 | 2016-02-10 | 株式会社栃木臨床病理研究所 | 抗腫瘍剤 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6797723B1 (en) | 1999-11-11 | 2004-09-28 | Eli Lilly And Company | Heterocycle substituted diphenyl leukotriene antagonists |
US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
EP2034022A1 (en) | 2007-09-10 | 2009-03-11 | Universite Libre De Bruxelles | Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus |
CN104011012B (zh) | 2012-01-10 | 2016-01-20 | 伊莱利利公司 | 白三烯b4拮抗剂化合物 |
NZ719169A (en) | 2013-12-20 | 2018-08-31 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH30449A (en) * | 1991-11-25 | 1997-05-28 | Lilly Co Eli | Substituted phenyl phenol leukotriene antagonists |
WO1996006604A2 (en) * | 1994-08-31 | 1996-03-07 | Eli Lilly And Company | Methods for identifying and treating resistant tumors |
US5910505A (en) * | 1997-03-21 | 1999-06-08 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma |
WO2001034198A2 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
AU1916501A (en) * | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
EP1231938A2 (en) * | 1999-11-11 | 2002-08-21 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
EP1231939A2 (en) * | 1999-11-11 | 2002-08-21 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
-
2001
- 2001-05-08 BR BR0110473-0A patent/BR0110473A/pt not_active IP Right Cessation
- 2001-05-08 MX MXPA02010974A patent/MXPA02010974A/es unknown
- 2001-05-08 CN CNB018093299A patent/CN1237968C/zh not_active Expired - Fee Related
- 2001-05-08 JP JP2001581820A patent/JP2003532675A/ja active Pending
- 2001-05-08 NZ NZ522387A patent/NZ522387A/en unknown
- 2001-05-08 KR KR1020027015033A patent/KR20030019372A/ko not_active Application Discontinuation
- 2001-05-08 EP EP01935770A patent/EP1326605A4/en not_active Withdrawn
- 2001-05-08 WO PCT/US2001/040697 patent/WO2001085166A1/en not_active Application Discontinuation
- 2001-05-08 AU AU2001261832A patent/AU2001261832A1/en not_active Abandoned
- 2001-05-08 CA CA002408622A patent/CA2408622A1/en not_active Abandoned
-
2002
- 2002-11-07 NO NO20025343A patent/NO20025343L/no not_active Application Discontinuation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5858391B2 (ja) * | 2013-04-22 | 2016-02-10 | 株式会社栃木臨床病理研究所 | 抗腫瘍剤 |
JP2016094403A (ja) * | 2013-04-22 | 2016-05-26 | 株式会社栃木臨床病理研究所 | 抗腫瘍剤 |
US9775836B2 (en) | 2013-04-22 | 2017-10-03 | Tochigi Institute Of Clinical Pathology | Antitumor agent |
US10149846B2 (en) | 2013-04-22 | 2018-12-11 | Tochigi Institute Of Clinical Pathology | Antitumor agent |
US10729683B2 (en) | 2013-04-22 | 2020-08-04 | Tochigi Institute Of Clinical Pathology | Antitumor agent |
Also Published As
Publication number | Publication date |
---|---|
NO20025343L (no) | 2003-01-09 |
BR0110473A (pt) | 2003-04-01 |
EP1326605A4 (en) | 2004-03-17 |
EP1326605A1 (en) | 2003-07-16 |
CA2408622A1 (en) | 2001-11-15 |
NZ522387A (en) | 2003-09-26 |
CN1429111A (zh) | 2003-07-09 |
MXPA02010974A (es) | 2004-09-06 |
KR20030019372A (ko) | 2003-03-06 |
WO2001085166A1 (en) | 2001-11-15 |
NO20025343D0 (no) | 2002-11-07 |
AU2001261832A1 (en) | 2001-11-20 |
CN1237968C (zh) | 2006-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression | |
JP5901529B2 (ja) | ベンゾヘテロサイクル誘導体の癌の予防及び治療又は癌転移抑制のための用途 | |
Hou et al. | VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth | |
Mirochnik et al. | Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth | |
US9463219B2 (en) | Method for treating brain cancer using a novel tumor suppressor gene and secreted factor | |
CN102300568A (zh) | Hif-1蛋白积聚的抑制剂 | |
Lallous et al. | Targeting binding function-3 of the androgen receptor blocks its co-chaperone interactions, nuclear translocation, and activation | |
Nakaki et al. | Enhanced transcription of the 78,000-dalton glucose-regulated protein (GRP78) gene and association of GRP78 with immunoglobulin light chains in a nonsecreting B-cell myeloma line (NS-1) | |
Yokoyama et al. | Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination | |
JP2003532675A (ja) | 癌細胞の増殖を阻害しそのアポトーシスを誘導する方法 | |
JP2006507327A (ja) | α5β1およびその細胞生存経路を調節する能力 | |
US20040053962A1 (en) | Methods for inhibiting proliferation and inducing apoptosis in cancer cells | |
Xu et al. | Ligustilide prevents thymic immune senescence by regulating Thymosin β15-dependent spatial distribution of thymic epithelial cells | |
Cellai et al. | Specific PAF antagonist WEB‐2086 induces terminal differentiation of murine and human leukemia cells | |
Labialle et al. | Characterization of the typical multidrug resistance profile in human uveal melanoma cell lines and in mouse liver metastasis derivatives | |
JP2006348006A (ja) | Ras信号伝達経路を標的にする血管新生、細胞増殖及び細胞転移抑制剤 | |
JP2006067968A (ja) | ヒト癌細胞の浸潤と転移を阻害する物質およびそのスクリーニング方法 | |
US20130157959A1 (en) | Use of hades as tumor suppressor target | |
KR102026142B1 (ko) | Crif1 억제제를 함유하는 항암 및 암전이 억제용 조성물 | |
WO2023140355A1 (ja) | 癌治療薬 | |
KR102571503B1 (ko) | 암질환 예방 또는 치료용 조성물 | |
WO2022089602A1 (zh) | 诊断和治疗化疗耐药小细胞肺癌的新靶点及其应用 | |
KR102140362B1 (ko) | Ei24 단백질 또는 이를 암호화하는 유전자를 유효성분으로 함유하는, 암 예방 및 치료용 약학적 조성물 | |
WO2017103625A1 (en) | Cancer treatment | |
EP2578227B1 (en) | Cancer therapy method |